Grant application to support clinical trial for treatment of Alzheimer’s disease
ISK Ltd and Harvard medical school submitted together grant application to support phase 1B clinical trial for treatment of Alzheimer’s disease.
PHASE 1B/2A Clinical trial started
The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.
Cooperation with Harvard Medical School (MGH)
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd
Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John
Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board
Prof. Joseph D Rosenblatt
Joseph D Rosenblatt is Professor of Medicine, Microbiology and Immmunology at the University of Miami Miller School of Medicine , and currently serves as the William Harrington Professor of Hematology and Chief of the University of Miami Division of Hematology.
He previously served as chief of the combined Division of Hematology – Oncology
Phase2a Nerofe study has begun in Rabin and Kaplan medical centers
Phase2a Nerofe study has begun in Rabin and Kaplan medical centers
PMWC 2018 conference – New Technology Presented
At PMWC 2018 conference Dr. Yoram Devary presented ISK new technology dealing with “personalized ImmunoOncology therapy”